Cocrystal Pharma COCP 深 滬
等待開盤 09-17 09:30:00 美东时间
1.14
0.000
0.00%
華盛通- 最 高1.1729
- 今 開1.13
- 成交量 4.68万股
- 最 低 1.11
- 昨 收 1.14
- 總市值 2.20万
- 52周最高 2.0299
- 市盈率 靜 --
- 換手率 243.18%
- 52周最低 0.76
- 委 比 95.09%
- 總股本 1.93万
- 歷史最高 66.00
- 量 比 0.83
- 振 幅 5.52%
- 歷史最低 0.76
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cocrystal Pharma Completes Dosing in Norovirus Phase 1b Study
An update from Cocrystal Pharma ( ($COCP) ) is now available. On September 9, 2...
09-09 20:41
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
Cocrystal Pharma announced completion of Phase 1b dosing for CDI-988, the first oral antiviral targeting norovirus. No serious adverse events reported. Preliminary efficacy results expected late 2026/early 2027. CDI-988 aims to inhibit all known norovirus strains, addressing a significant unmet medical need.
09-09 11:00
Cocrystal Pharma strengthens board with antiviral expert appointment
An update from Cocrystal Pharma ( ($COCP) ) is now available. On August 17, 202...
08-18 04:52
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
Cocrystal Pharma appoints Carol Brosgart, MD, to its Board of Directors. Dr. Brosgart, with decades of experience in antiviral therapy and epidemiology, will contribute to advancing the company's antiviral pipeline, including CDI-988 for norovirus. She previously worked at Gilead Sciences and holds leadership roles at multiple biotech companies. Cocrystal focuses on developing novel antiviral therapeutics targeting noroviruses, influenza, coronav...
08-17 15:17
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from the same period last year. The company reported $105.000 thousand in sales this q...
08-13 20:23
OPKO Health Boosts Stake in Cocrystal Pharma Financing
Cocrystal Pharma ( ($COCP) ) has shared an announcement. On August 3, 2026, Coc...
08-03 19:48
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Cocrystal Pharma announced a $5 million investment from long-term investor OPKO Health to advance its lead norovirus program toward Phase 1b data expected late in 2026. OPKO acquired 5,474,053 shares at $0.9134 per share. Both companies expressed confidence in Cocrystal's science and pipeline, which includes treatments for influenza, coronaviruses, and hepatitis C.
08-03 11:00
Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_06012026_COCP_Bautz.pdf
06-01 23:07
Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections represent significant unmet
05-26 20:09
